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Background: Neoadjuvant chemoradiation might increase anastomotic leakage and stenosis in patients with
esophageal cancer treated with neoadjuvant chemoradiation and esophagectomy. The aim of this study was to
determine the influence of radiation dose on the incidence of leakage and stenosis.
Methods: Fifty-three patients with esophageal cancer received neoadjuvant chemoradiation (23 × 1.8 Gy) (combined
with Paclitaxel and Carboplatin) followed by a transhiatal esophagectomy between 2009 and 2011. On planning CT,
the future anastomotic region was determined and the mean radiation dose, V20, V25, V30, V35 and V40 were
calculated. Logistic regression analysis was conducted to examine determinants of anastomotic leakage and stenosis.
Results: Anastomotic leaks occurred in 13 of 53 patients (25.5%) and anastomotic stenosis occurred in 24 of 53
patients (45.3%). Median follow-up was 20 months. Logistic regression analysis showed that mean dose, V20-V40, age,
co-morbidity, method of anastomosis, operating time and interval between last radiotherapy treatment and surgery
were not predictors of anastomotic leakage and stenosis.
Conclusions: A radiation dose of 23 × 1.8 Gy on the future anastomotic region has no influence on the occurrence of
anastomotic leakage and stenosis in patients with esophageal cancer treated with neoadjuvant chemoradiation
followed by transhiatal esophagectomy.
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Esophageal cancer is the eighth most commonly diag-
nosed type of cancer worldwide and it is the sixth leading
cause of cancer deaths [1]. The incidence of esophageal
carcinoma in the Netherlands, especially adenocarcinoma,
has rapidly risen from 1731 new cases in 2000 to 2499
in 2010 [2]. According to the current Dutch guidelines,
the preferred curative treatment for non-metastatic dis-
ease is neoadjuvant chemoradiation followed by trans-
hiatal or transthoracic esophagectomy [3]. Patients with
an irresectable tumor, or patients who are too vulnerable* Correspondence: grard.nieuwenhuijzen@catharinaziekenhuis.nl
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unless otherwise stated.for surgery are often proposed for definitive chemoradia-
tion which show encouraging results [4,5].
Surgical treatment has an acceptable mortality in high
volume centres, but high rates of post-operative morbidity
have still been described [6-9]. However, pulmonary com-
plications and anastomotic complications like leakage and
stenosis are still common [7-9]. The incidence of anasto-
motic leakage reported in the literature ranges from 5.7%
to 41% [6-16]. Incidence rates of anastomotic stenosis are
even higher ranging from 21.8% to 44% [6,10-12].
Factors like co-morbidity, nutrition status, anastomotic
location, anastomotic technique and blood loss during
surgery are hypothesised to be related to the develop-
ment of anastomotic leakage and stenosis [10,17].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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developing anastomotic complications. Studies compar-
ing neoadjuvant chemoradiation followed by surgery
with surgery alone showed conflicting results with re-
spect to the risk of anastomotic leakage and stenosis due
to the neoadjuvant treatment [8,11,15,16,18]. However,
these studies incorporated heterogeneous patient groups,
radiation fields and anastomotic locations. A recent
study showed that in patients receiving neoadjuvant che-
moradiation median radiation dose to the gastric fundus
was an independent predictor for early anastomotic
complications in patients with an Ivor-Lewis esophagec-
tomy [19]. However in an intrathoracic anastomosis the
region below the gastric fundus rather than the gastric
fundus itself is used for the anastomosis because a
shorter gastric conduit is needed when compared with a
cervical anastomosis, raising the question of whether or
not other factors are responsible for the observed differ-
ence. When compared with an Ivor-Lewis esophagec-
tomy, in patients receiving a transhiatal resection and a
cervical anastomosis, a larger part of the irradiated gas-
tric fundus is used for the anastomosis. Hence, the aim
of our study was to determine the influence of radiation
dose on the incidence of anastomotic complications
(leakage and stenosis) in a more homogeneous patient
group with distal esophageal or gastro-esophageal junc-
tion cancer undergoing neoadjuvant chemoradiation
followed by a transhiatal esophagectomy and cervical
anastomosis. In all of these patients the fundus of the
stomach was irradiated to a varying degree.
Methods
Study population
Between 2009 and 2011 we included 53 consecutive
patients with distal esophageal cancer (C15.5) or gastro-
esophageal junction cancer (C16.0), who received neoadju-
vant chemoradiation followed by an open or laparoscopic
transhiatal esophagectomy with a left cervical anastomosis.
Median follow-up duration was 20 months (range 0.2-25).
All patients had histologically proven adenocarcinoma or
squamous cell carcinoma with no evidence of distant me-
tastases (cT1-3, N0-3, M0; TNM 7) [20]. Cancer staging
included clinical examination, esophago-gastroscopy with
biopsies, endoscopic ultrasonography (EUS), external
ultrasonography of the cervical region, computed tomog-
raphy (CT) of the chest and abdomen and a positron
emission tomography fused with CT (PET- CT). This re-
search is reviewed by the local medical ethics committee
but the Dutch Medical Research (Human Subjects) Act is
not applicable to this study.
Surgery
Surgical treatment consisted of a laparoscopic or open
transhiatal esophagectomy with gastric tube interponate[18]. A left cervical anastomosis was performed (at sur-
geon’s preference) end-to-end with hand-sewn continu-
ous or interrupted sutures or side-to-side with a stapling
device (Collard anastomosis [21]).Neoadjuvant chemoradiation regimen
The neoadjuvant regimen consisted of Three-Dimensional
Conformal Radiotherapy (3D-CRT) to a total dose of
41.4 Gy (23 fractions of 1.8 Gy, 5 fractions a week) combined
with Paclitaxel (50 mg/m2) and Carboplatin (AUC= 2) ad-
ministered by intravenous infusion on days 1, 8, 15, 22
and 29. The Gross Tumor Volume (GTV) included all
visible tumor and pathologically enlarged lymph nodes
(determined by CT, PET-CT or EUS). The Clinical Target
Volume (CTV) was defined by the GTV (node and
tumor) plus the area of regional lymph nodes up to at
least 3 cm in cranial and caudal extension of the esopha-
gus from the tumor GTV. To ensure adequate margins
around the macroscopic tumor, a minimum CTV-GTV
margin of 0.5 cm was required. For distal tumors, the
caudal margin should follow the wall of esophagus and
cardia. The margin in the direction of the wall of the car-
dia was limited to 2 cm. The Planning Target Volume
(PTV) consisted of the CTV plus a margin of 1 cm in all
directions (Figure 1). These margins were chosen as these
are the margins we use in clinical practice. We realise
that these margins should preferably be patient specific
and dependent on, for example, the individual tumor mo-
tion. Because of these margins, the fundus in all patients
with distal or junction tumors was irradiated to a varying
degree.Calculation of RT dose to the anastomotic region of
interest
The future anastomotic region was retrospectively deter-
mined on the preoperative planning CT using the
Philips Pinnacle treatment planning system version 9.0.
CT slice thickness and separation were 3 mm. The most
proximal part of the stomach was determined. From that
point, a 5 cm distal (coronal plane) vertical line was
drawn. On the transversal plane the distal margin at
7 cm was drawn. We used a 2 cm margin from the lesser
curvature and a 2 cm margin from the most proximal
part of the stomach (Figure 2). These margins are deter-
mined after consultation of the operating surgeon. The
future anastomotic region in all patients was determined
by the first author.
From this future anastomotic region we calculated the
following parameters: volume, mean dose, V20, V25,
V30, V35 and V40 (percentage irradiated volume receiv-
ing more than respectively 20, 25, 30, 35 and 40 Gy). In
order to quantify the effect of a larger CTV-PTV margin
on the parameters we repeated the analysis with an
Figure 1 Example pictures of dose distribution.
Figure 2 Example of a planning CT in which the future anastomotic region is drawn.
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volume + 0.5 cm).Classification of leakage and stenosis
Anastomotic leakage was defined as any clinical evi-
dence of leakage of salivary fluid in the cervical region,
gastric conduit necrosis or evidence of anastomotic leak-
age on CT or with esophago-gastroscopy (CTCAE grade
1–5) [22]. Anastomotic stenosis was defined as dysphagiaTable 1 Characteristics of patients with or without anastomot
followed by transhiatal esophagectomy
Anastomotic le
Yes (n = 13)
Mean age 62.4 [41–77]
Gender:
Male (n = 49) 13 (27%)
Female (n = 4) 0 (0%)
BMI 27.5 [21–41]
Co-morbidity:
0 (n = 13) 3 (23%)
1 (n = 18) 4 (22%)
2 or more (n = 22) 6 (27%)
ASA classification:
I (n = 8) 3 (38%)
II (n = 41) 9 (22%)
III (n = 4) 1 (25%)
Histologic type:
Adenocarcinoma (n = 49) 12 (24%)
Squamous cell carcinoma (n = 4) 1 (25%)
Mean volume (cm3) 53.1 [33–71]






OR time (min) 172 [118–329]
Resection type:
Open (n = 21) 7 (33%)
Laparoscopic (n = 32) 6 (19%)
Method of anastomosis:
End-to-end continuous (n = 33) 6 (18%)
End-to-end interrupted (n = 11) 4 (36%)
Side-to -side stapler (n = 9) 3 (33%)
Interval last RT– surgery (days) 70 [40–127]
Hospital stay (days) 22 [13–71]for which one or more endoscopic dilatation(s) of the
anastomosis was needed.Statistical analysis
Differences in patient, tumor and dose characteristics
between patients with or without anastomotic leakage or
anastomotic stenosis were compared using the Mann–
Whitney U test and the chi-square test. Univariable and
multivariable logistic regression analyses were conductedic leakage, treated with neo-adjuvant chemoradiation
akage
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tomotic leakage or stenosis. All analyses were performed
using Statistical Package for Social Sciences version 19.0
(SPSS Inc., Chicago, IL, USA). All reported p-values below
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Figure 3 Percentage of patients with and without leakage as a
function of DVH parameters. Error bars represent 1 SD.Results
All 53 patients completed the neoadjuvant chemoradia-
tion regimen followed by transhiatal esophagectomy
after a therapy free interval of 4–18 weeks, with a me-
dian of 9 weeks. The mean irradiation dose to the anas-
tomotic region was 30.3 Gy [range 6–42], with a mean
volume of 48.2 cm3 [range 21–92]. Postoperatively, 13 of
53 patients (25.5%) developed an anastomotic leak and
six patients (11.3%) needed a surgical re-intervention; of
these, 4 patients (7.5%) required re-intervention because
of severe anastomotic problems. Two patients needed
thoracic drainage for thoracic empyema. In three pa-
tients, drainage of a cervical abscess was performed.
One patient needed re-intervention for an abdominal
dehiscence. Two patients (3.8%) died in hospital: one pa-
tient died because of Acute Respiratory Distress Syn-
drome and another of myocardial infarction. To date, 15
patients (28.3%) have died during follow-up, with me-
dian follow-up duration of 20 months. Of these patients,
10 died because of cancer recurrence, 3 patients died
from a non-disease-related cause and 2 patients had an
unknown cause of dead.
Patients with an anastomotic leakage were hospitalised
significantly longer than patients without anastomotic
leakage (22 vs. 13 days, p = 0.001). Between the groups
with or without anastomotic leakage no significant dif-
ferences in age, gender, BMI, co-morbidity, ASA classifica-
tion, histology, type of operation, duration of the
procedure, method of anastomosis, anastomotic region
volume, mean dose and time between the end of the neo-
adjuvant treatment and surgery were observed (Table 1).
Comparable results on leakage rate were observed using
the anastomotic region volume + 0.5 cm. In Figure 3 we
depicted the percentage of patients with and without leak-
age as a function of DVH parameters.
Clinically, anastomotic stenosis occurred in 24 of 53
patients (45.3%). Between the groups with or without
anastomotic stenosis, no significant differences in age,
gender, BMI, co-morbidity, ASA classification, histology,
type of operation, operating time, method of anasto-
mosis, anastomotic region volume, mean dose and time
between the end of the neoadjuvant treatment and sur-
gery were observed (Table 2). Comparable results on
stenosis rate were observed using the anastomotic region
volume +0.5 cm. In Figure 4 we depicted the percentage
of patients with and without stenosis as a function of
DVH parameters.Univariable logistic regression analysis showed that
mean radiation dose was a borderline significant pre-
dictor for anastomotic leakage. In addition univariable
analysis also showed that patients with a high V20 per-
centage were less likely to develop anastomotic leakage.
However, multivariable analysis showed that V20 per-
centage and mean dose to the proposed area of the anas-
tomosis were not significant predictors for anastomotic
leakage anymore. Again, all other factors like age, BMI,
co-morbidity (including cardiovascular and pulmonary
co-morbidity separately), histology, ASA classification,
type of resection, operating time, method of anasto-
mosis, mean dose, V25-V40 and interval between the
end of the neoadjuvant treatment and surgery were not
significant predictors for anastomotic leakage in our uni-
variable analysis and were therefore not analysed in the
multivariable analysis (Table 3). Furthermore, the same
analyses for the anastomotic region volume + 0.5 cm had
no influence on the results.
Univariable analysis showed that age and interval be-
tween the end of the neoadjuvant treatment and surgery
were borderline significant. Anastomotic stenosis devel-
oped significantly more often in patients without comor-
bidity compared with patients with > =1 comorbidity.
However, multivariable analysis showed that factors such
as age, co-morbidity and interval between radiotherapy
dose and surgery were not significant predictors for
anastomotic stenosis. All other factors like BMI, cardio-
vascular and pulmonary co-morbidity, histology, ASA
classification, type of operation, operating time, method
of anastomosis, mean dose, and V20-V40 were not sig-
nificant predictors for anastomotic stenosis in our uni-
variable analysis and were therefore not analysed in the
multivariable analysis (Table 4). Again, the same analyses
for the ROI + 0.5 cm had no influence on the results ob-
served in our analysis.
Table 2 Characteristics of patients with or without anastomotic stenosis, treated with neo-adjuvant chemoradiation
followed by transhiatal esophagectomy
Anastomotic stenosis
Yes (n = 24) No (n = 29) p-value
Mean age 61.3 [41–78] 65.4 [48–82] 0.30
Gender:
Male (n = 49) 21 (43%) 28 (57%)
Female (n = 4) 3 (75%) 1 (25%) 0.32
BMI 26.6 [19–41] 26.7 [21–35] 0.68
Co-morbidity:
0 (n = 13) 9 (69%) 4 (31%)
1 (n = 18) 8 (44%) 10 (56%)
2 or more (n = 22) 7 (32%) 15 (68%) 0.10
ASA classification:
I (n = 8) 4 (50%) 4 (50%)
II (n = 41) 19 (46%) 22 (54%)
III (n = 4) 1 (25%) 3 (75%) 0.69
Histologic type:
Adenocarcinoma (n = 49) 22 (45%) 27 (55%)
Squamous cell carcinoma (n = 4) 2 (50%) 2 (50%) 0.84
Volume (cm3) 48.3 [29–81] 48.1 [21–92] 0.92
Mean dose (Gy) 31.2 [6–42] 29.6 [8–42] 0.38
V20 84.9% 83.4% 0.27
V25 68.8% 58.5% 0.24
V30 59.5% 50.1% 0.30
V35 52.9% 43.1% 0.28
V40 40.1% 28.8% 0.14
OR time (min) 184 [118–329] 182 [138–292] 0.75
Resection type:
Open (n = 21) 11 (52%) 10 (48%)
Laparoscopic (n = 32) 13 (41%) 19 (59%) 0.40
Method of anastomosis:
End-to-end continuous (n = 33) 15 (45%) 18 (55%)
End-to-end interrupted (n = 11) 7 (64%) 4 (36%)
Side-to -side stapler (n = 9) 2 (22%) 7 (78%) 0.18
Interval last RT– surgery (days) 65 [37–118] 73 [31–127] 0.31
Hospital stay (days) 14 [6–35] 16 [6–71] 0.63
Anastomotic leakage (n = 13) 7 (54%) 6 (46%) 0.48
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In this study we determined the influence of radiation
dose in the future anastomotic region on developing
anastomotic leakage and stenosis in patients with distal
esophageal or esophago-gastric junction cancer (cT1-3,
N0-3, M0) treated with neoadjuvant chemoradiation
followed by transhiatal esophagectomy with gastric tube
reconstruction and a left cervical anastomosis. Overall,25.5% of patients developed anastomotic leakage and
45.3% developed anastomotic stenosis. Our study identi-
fied no significant predictors of anastomotic leakage and
stenosis. In contrast with a recent study [19], radiation
dose did not have a significant influence on developing
anastomotic leakage and stenosis.
This study shows that variations in mean dose and V20
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Figure 4 Percentage of patients with and without stenosis as a
function of DVH parameters. Error bars represent 1 SD.
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strated that the mean radiation dose on the gastric fundus
dose was an independent predictor for early anastomotic
complications like leakage [19]. The recent study had a
different neoadjuvant treatment regime (36 Gy in 20 frac-
tions combined with 5-FU and cisplatin) and a different
surgical procedure (Ivor-Lewis) compared with the
current study. Although the authors did not describe their
surgical procedure in detail, the region below the gastric
fundus at the level of the watershed of the gastroepiploic
vessels is most commonly used for the intra-thoracic anas-
tomosis in the Ivor-Lewis procedure. In a cervical anasto-
mosis, the gastric tube should be longer and the
anastomosis reconstructed from the fundus region of the
stomach. Hence, the radiation dose on the future anasto-
motic region could even be less than the dose suggested
by the authors and other factors could potentially be more
responsible for the observed effects than the irradiation on
the gastric fundus itself. Therefore, it is even more re-
markable that we did not observe a negative effect of ir-
radiation to the fundus on anastomotic complications in
our series. Furthermore, the authors did not have a clear
definition of anastomotic leakage; in addition, their de-
scription of the determined anastomotic region was not
clear and not reproducible.
In our study, variations in mean dose and V20-V40
showed no significant influence on developing anasto-
motic stenosis. This is in concordance with a study in
which it was demonstrated that neoadjuvant chemoradi-
ation was not a predictor for the incidence of benign
anastomotic strictures. However, this study did show
that neoadjuvant chemoradiation was an independent
predictor for patients with refractory strictures (requir-
ing >10 dilatations) [18]. Furthermore, a recent study
showed a higher mean radiation dose in patients with
anastomotic stenosis [19].Comorbidity in our study did not have an influence on
the development of anastomotic leakage or stenosis.
This is in concordance with another study showing that
major co-morbidity is not an independent predictor for
early anastomotic complications like leakage [19]. Another
study confirmed these results and showed that diabetes,
chronic obstructive pulmonary disease and coronary ar-
tery disease had no influence on developing anastomotic
leakage [8].
Anastomotic leakage rates vary between studies, with
leakage rates between 5.7 and 41% [6-16]. This might be
the result of the various definitions of anastomotic leak-
age. Some studies define leakage as clinical or radio-
logical evidence of leakage. However, other definitions
include only clinical leakage or anastomotic leakage re-
quiring re-intervention.
In this study, anastomotic leakage was defined as every
evidence of leakage (including all clinical and radiologic
evidence of leakage), explaining the relatively high rate
of anastomotic leakage (25.5%) in our study compared
with others [6-15]. As summarised in Table 5, random-
ized controlled trials that have compared neo-adjuvant
chemoradiation with subsequent surgery versus surgery
alone show different results with regard to the incidence
of anastomotic leakage and the influence of chemoradia-
tion on leakage rate. The incidence of leakage rates in
those RCTs ranged from 3% to 30% [16,23-30]. The in-
fluence of neo-adjuvant chemoradiation on leakage rate
is often not statistically tested. Furthermore, the differ-
ences in leakage rate between patients receiving neo-
adjuvant chemoradiation with surgery vs. surgery alone
are small.
When comparing our leakage rate with the rate re-
ported in a recent Dutch multicentre randomized trial
studying the role of neo-adjuvant chemoradiation with
the same regime as our study, our leakage rate appears
to be comparable [16].
The influence of (chemo)radiation on anastomotic
leakage has also been studied in other solid tumors like
rectal cancer. A large randomized and a large retrospect-
ive study showed that neo-adjuvant chemoradiation did
not influence anastomotic leakage rates following Total
Mesorectal Excision in patients with rectal cancer [31,32].
Another large Dutch Multicentre RCT showed no differ-
ence in anastomotic leakage rates between patients who
received short course neoadjuvant radiotherapy followed
by surgery compared to surgery alone. However, they did
observe significantly more post-operative wound compli-
cations in the radiotherapy group [33].
Anastomotic stenosis occurred in 45.3% of the patients;
however, other studies have shown a lower incidence
(21.8-41.7%) [6,11,12,18]. As shown in Table 5, anasto-
motic stenosis is often not registered in randomized con-
trolled trials. Only two studies mention anastomotic
Table 3 Predictors of anastomotic leakage in patients with distal esophageal or esophago-gastric junction cancer
treated with neoadjuvant chemoradiation followed by transhiatal esophagectomy
Univariable analysis Multivariable analysis
OR 95% CI p-value OR 95% CI p-value
Age 0.99 0.93-1.05 0.63
BMI 1.07 0.91-1.24 0.42
Co-morbidity:
0 0.80 0.16-3.94 0.78
1 0.76 0.18-3.26 0.71
2 or more ref
Cardiovascular co-morbidity:




Yes 1.7 0.36-8.04 0.50
ASA classification:
I 2.13 0.43-10.68 0.36
II ref
III 1.19 0.11-12.82 0.89
Histology:
Adenocarcinoma ref
Squamous cell carcinoma 0.98 0.10-10.83 0.98
Mean dose 1.00 1.00-1.00 0.07 1.00 1.00-1.00 0.67
V20 0.97 0.96-1.00 0.03 0.96 0.90-1.02 0.21
V25 0.99 0.97-1.01 0.23
V30 0.99 0.98-1.01 0.25
V35 0.99 0.97-1.01 0.28
V40 0.99 0.97-1.01 0.32
OR time 0.99 0.97-1.01 0.25
Resection type:




EE interrupted 2.57 0.57-11.69 0.22
Side-to -side stapler 2.25 0.44-11.65 0.33
Interval last RT- surgery 1.00 0.83-1.20 0.99
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moradiation with subsequent surgery vs. surgery alone.
The incidence of anastomotic stenosis in this study is rela-
tively high; however, it is in concordance with a study in
which the incidence of anastomotic stricture was 44% in
patients with an end-to-end anastomosis [10].
Anastomotic leakage was not a predictor for anasto-
motic stenosis in our study. This is not supported by otherstudies in which anastomotic leakage was found to be an
independent predictor for anastomotic stenosis [11,12,18].
This difference might be a result of the relatively small
number of patients and the relatively high anastomotic
leakage rate identified in the current study.
Other factors besides chemoradiation that might influ-
ence anastomotic problems are, according to the litera-
ture, type of resection (transthoracic vs. transhiatal) and
Table 4 Predictors of anastomotic stenosis in patients with distal esophageal or esophago-gastric junction cancer
treated with neoadjuvant chemoradiation followed by transhiatal esophagectomy
Univariable analysis Multivariable analysis
OR 95% CI p-value OR 95% CI p-value
Age 0.96 0.90-1.01 0.14 0.99 0.92-1.06 0.66
BMI 0.99 0.87-1.14 0.92
Co-morbidity:
0 4.82 1.10-21.19 0.04 3.17 0.54-18.82 0.20
1 1.71 0.77-6.24 0.41 1.39 0.34-5.67 0.64
2 or more ref
Cardiovascular co-morbidity:




Yes 0.96 0.23-4.06 0.96
ASA classification:
I 1.16 0.25-5.72 0.85
II ref
III 0.39 0.04-4.03 0.43
Histology:
Adenocarcinoma ref
Squamous cell carcinoma 1.23 0.16-9.43 0.84
Mean dose 1.00 1.00-1.00 0.50
V20 1.00 0.98-1.03 0.81
V25 1.01 0.99-1.03 0.24
V30 1.01 0.99-1.03 0.28
V35 1.01 0.99-1.03 0.27
V40 1.01 0.99-1.03 0.21
OR time 1.00 0.99-1.01 0.87
Resection type:




EE interrupted 2.10 0.51-8.57 0.30
Side-to -side stapler 0.34 0.06-1.90 0.22
Interval last RT- surgery 0.88 0.74-1.04 0.14 0.92 0.77-1.11 0.39
Anastomotic leakage 1.58 0.45-5.55 0.48
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In the studied RCTs, both types of surgery have been
often used and anastomotic location was mostly cervical
or not mentioned at all (Table 5). Based on these hetero-
geneous RCTs, it is difficult to determine factors that in-
fluence anastomotic leakage and stenosis. Therefore, we
investigated a homogenous patient population with thesame type of resection and a strictly defined cervical
anastomotic location.
This study is unique, but also has some limitations.
The study population is relatively small; however, the
group used here is more homogenous than others with re-
spect to the uniform treatment and type of anastomosis.
Furthermore, the determination of the future anastomotic
Table 5 Anastomotic complications in randomised trials comparing neo-adjuvant chemoradiation and surgery with
surgery alone
Anastomotic complications neo-adjuvant chemoradiation and surgery vs. surgery alone






CRT + S S Chemo RT CRT + S S CRT + S S
Nygaard et al. 1992 [23] 34 38 Cisplatin 35.0 Gy (20 × 1.75) TTE Not mentioned 6% 3% Not Mentioned
Le Prise et al. 1993 [24] 41 45 Cisplatin 5-FU 20.0 Gy (10 × 2.0) Not mentioned Not mentioned Not Mentioned Not Mentioned
Walsh et al. 1996 [25] 58 55 Cisplatin 5-FU 40.0 Gy (15 × 2.67) TTE or THE Cervical 3% 4% Not Mentioned
Bosset et al. 1997 [26] 143 139 Cisplatin 37.0 Gy (10 × 3.7) TTE >80% Not mentioned Not Mentioned Not Mentioned
Lee et al. 2004 [27] 51 50 Cisplatin 5-FU 45.6 Gy (38 × 1.2) TTE Cervical Not Mentioned 14% 17%
Urba et al. 2001 [28] 50 50 Cisplatin 5-FU
Vinblastin
45.0 Gy (30 × 1.5) THE Cervical 15% 8% Not Mentioned
Burmeister et al. 2005 [29] 128 128 Cisplatin 5 FU 35.0 Gy (15 × 2.3) TTE Thoracic or
Cervival
5% 5% 19% 24%
Tepper et al. 2008 [30] 30 26 Cisplatin 5-FU 50.4 Gy (28 × 1.8) TTE or THE Not mentioned Not Mentioned Not Mentioned
Van Hagen et al. 2012 [16] 178 188 Carboplatin
Paclitaxel
41.4 Gy (23 × 1.8) TTE or THE Cervical 22% 30% Not Mentioned
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geon, may be prone to a certain degree of subjective
variability. However, since we have uniformly determined
the anastomotic region within a pre-defined distance from
the most proximal part of the stomach, we believe that the
comparison between groups is accurate enough to draw
firm conclusions from the results.
Furthermore, we were not able to compensate breathing-
induced organ motion. This could have influenced the cal-
culated dose to the region of interest. However because
the PTV consisted of the CTV plus a margin of 1 cm in all
directions we do not think this will have a significant influ-
ence on our results. As in other studies looking at the
correlation between radiation induced morbidity and
anastomotic complications, the influence of day-to-day
treatment variations on the dose to the region could not
be quantified as we do not have CBCT imaging data of
these patients, which is a clear limitation. Realising this, it
is even more striking that we did not observe a correlation
between dose and morbidity, as including day-to-day vari-
ations will only blur the dose distributions we want to cor-
relate with morbidity even more. In this study we did not
measure esophagitis grade after chemoradiation. Recent
study in lung cancer patients showed association between
higher V50 and esophagitis [34]. The number of patients
with esophagitis in our study will be comparable with re-
cent published results from the CROSS II trial with the
same chemoradiation regimen. They observed that 19% of
the patients developed esophagitis [16].
Conclusions
This study demonstrates that radiation dose on the future
anastomotic region did not have a significant influence onthe occurrence of anastomotic leakage and stenosis in pa-
tients with esophageal cancer treated with this commonly
used regimen of neoadjuvant chemoradiation followed by
transhiatal esophagectomy and left cervical anastomosis.
Although with a relative small study population, our
study is important for clinical practice since it suggests
that radiation to the future anastomotic region within a
regimen of neo-adjuvant chemoradiation with a moder-
ate total dose has no apparent negative effect of anasto-
motic complications.
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